drugset / Trial / NCT01396408
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research is being done because there is no treatment that will cure this type of cancer. Although some types of chemotherapy can cause this cancer to shrink for a time, better options are needed.
Timeline
- Start
- 2012-02-09
- Primary completion
- 2015-07-06
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sunitinib | Small molecule | 50 mg | Oral |
| Comparator | Temsirolimus | Small molecule | 25 mg | Intravenous |
Indications
No indication recorded.